Table 4

Comparison of clinical characteristics between predicted subgroups of venous metastasis

Predicted NM

Predicted M

P value


Patient cohort (n = 198)

n = 137

n = 61

Gender(male/female)

121/16

53/8

0.9601

Age(yr, mean ± SD)

49.99 ± 11.22

50.15 ± 9.54

0.8235

Number of nodule(1/2/3/4)

117/18/2

55/4/1/1

0.2603

Tumor capsule(complete/none)

53/84

24/37

0.9441

Cirrhosis(no/yes)

8/129

5/56

0.7584

AFP(log2-transformed, mean ± SD)

6.79 ± 3.96

8.08 ± 4.56

0.0395

TB(μmol/L, median(25-75%))

15.4(12.1-20.2)

17.4(11.4-22.1)

0.2954

ALT(μ/L, median(25-75%))

43(31-61)

49(32-66)

0.3929

OKUDA stage(0/1)

119/18

49/12

0.3325

CLIP stage(0/1/2/3/4)

64/49/22/1/1

28/15/12/4/2

0.0509

BCLC stage(0/A/B/C)

15/103/14/5

7/35/7/12

0.0022

TNM stage(I/II/III)

65/57/15

23/23/15

0.0441

Child-Pugh class(A/B)

132/5

57/4

0.5910


P value: Comparison between clinic pathological indicators of non-metastatic and metastatic groups was conducted using chi-square test for discrete variables and Wilcoxon test for continuous variables.

Zeng et al. BMC Genomics 2012 13(Suppl 8):S14   doi:10.1186/1471-2164-13-S8-S14

Open Data